After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Acadia Pharmaceuticals Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Acadia Pharmaceuticals Inc is $4.06B. A total of 1.2 million shares were traded on the day, compared to an average of 2.07M shares.
In the most recent transaction, Daly James M sold 30,000 shares of ACAD for 22.37 per share on Nov 10 ’25. After the transaction, the Director now owns 4,041 company shares. In a previous transaction on Nov 10 ’25, James M Daly bought 30,000 shares at 22.37 per share.
Among the insiders who sold shares, Schneyer Mark C. disposed of 3,498 shares on Sep 15 ’25 at a per-share price of $23.65. This resulted in the EVP, CHIEF FINANCIAL OFFICER holding 43,447 shares of ACAD after the transaction. In another insider transaction, GAROFALO ELIZABETH A. sold 1,600 shares at $25.98 per share on Sep 02 ’25. Company shares held by the Director now total 25,382.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, ACAD has a high of $26.65 and a low of $13.40.
As of this writing, ACAD has an earnings estimate of $0.15 per share for the current quarter. EPS was calculated based on a consensus of 15.0 estimates, with a high estimate of $0.23 per share and a lower estimate of $0.1. The company reported an EPS of $0.86 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ACAD’s latest balance sheet shows that the firm has $520.71M in Cash & Short Term Investments as of fiscal 2021. There were $64.43M in debt and $96.07M in liabilities at the time. Its Book Value Per Share was $5.42, while its Total Shareholder’s Equity was $540.89M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ACAD is Buy with a score of 4.05.
